Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide-48-week results from the DYAD study

AUTHORS

C.-P. Rolle1,2, J. Castano1, V. Nguyen1, F. Hinestrosa1,3, E. DeJesus1,3


INSTITUTIONS

1Orlando Immunology Center, Orlando, United States, 2Emory University Rollins School of Public Health, Global Health, Atlanta, United States, 3University of Central Florida College of Medicine, Orlando, United States
25 July 2024
English
Download e-poster
View abstract

Presenter

Federico Hinestrosa

Federico Hinestrosa